ACM
SIOX

ACT Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

ACT Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$41K Hold
146,500
– – 0.06% 59
2022
Q2 		$53K Hold
146,500
– – 0.07% 62
2022
Q1 		$98K Sell
146,500
-38,500
-21% -$32.7K 0.1% 67
2021
Q4 		$239K Hold
185,000
– – 0.17% 63
2021
Q3 		$401K Hold
185,000
– – 0.21% 66
2021
Q2 		$506K Buy
+185,000
New +$460K 0.26% 67

Other funds holding SIOX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $195M AUM 29.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

ACT Capital Management's SIOX Position: Q3 2022 in Review

ACT Capital Management held its Sio Gene Therapies Inc. Common Stock (SIOX) position steady in Q3 2022 at 146,500 shares worth $41K. The position accounts for 0.06% of the portfolio, ranked #59.

ACT Capital Management first reported a position in SIOX in Q2 2021 and has held it in 6 quarters since. The position peaked at $506K in Q2 2021. 40 funds tracked by Wall St. Rank hold SIOX as of Q3 2022.

  • ACT Capital Management held 146,500 shares of Sio Gene Therapies Inc. Common Stock worth $41K as of Q3 2022.
  • ACT Capital Management left its Sio Gene Therapies Inc. Common Stock share count unchanged in Q3 2022.
  • Sio Gene Therapies Inc. Common Stock made up 0.06% of ACT Capital Management's portfolio in Q3 2022, its #59 holding.
  • ACT Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $506K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.